Will you be at DIA EuroMeeting? Let's meet!

Science, Service, Solutions at Stand L2

Worldwide Clinical Trials has the experience to understand and navigate the complexities of conducting global clinical studies.  We partner with you to provide unrivaled therapeutic expertise and operational excellence across all phases of development in neuroscience, cardiovascular disease, inflammatory disorders and rare diseases.


Our combined leadership expertise, unique geographic placement and highly experienced operational team means we have the proven capabilities to deliver your studies on-time, every time!

Visit us at Booth #L2 or schedule a meeting today!

Michael F Murphy, MD, PhD
Chief Medical and Scientific Officer
Paola Antonini, MD, PhD
Senior Vice-President, Scientific Affairs

Despite the global burden of cardiovascular disease, investment in cardiovascular drug development has stagnated over the past two decades, with relative underinvestment compared to other therapeutic areas. There are multiple reasons for this trend, but of primary concern is the high cost of conducting cardiovascular outcomes trials (CVOT) in the current regulatory and commercial environment that demands assessment of risks and benefits, using clinically evident cardiovascular endpoints against a background of established therapies.  Frequently, the absolute treatment difference over existing therapies in these large, logistically complex trials, has un-clear implications regarding the value that should be ascribed to innovative therapy. Because of their scale and international footprint, standard of care variations across the entire sample make results interpretation contingent on examination of subgroups, sequence of treatment prior to randomization, or regional standards of care which can modify treatment effects.

Read more
Tomislav Babic, MD, PhD
Vice President of Medical and Scientific Affairs / Neuroscience

Idiopathic Parkinson’s Disease (IPD) is the second most common neurodegenerative disorder after Alzheimer’s
disease (AD). Despite its prevalence, approximately 5 to 10% of patients with IPD are misdiagnosed, and conversely, up to 20% of patients diagnosed with IPD reveal alternative diagnoses upon autopsy, such as multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, AD type pathology, and cerebrovascular disease. Well-established diagnostic criteria such as the UK PD Society Brain Bank criteria have been in use in clinical trials for over 20 years; however, it has been suggested that an accuracy of 90% is the best that can be achieved with clinical assessment and clinical diagnostic criteria. In an effort to update these criteria to reflect our more recent understanding of IPD and increase diagnostic specificity, the Movement Disorders Society (MDS) has recently published Clinical Diagnostic Criteria for Parkinson’s disease (MDS-PD), designed specifically for use in clinical research, but also as a general guide to clinical diagnosis of IPD consequent to Lewy body pathology.

Read More

Michael F. Murphy, MD, PhD
Chief Medical and Scientific Officer

While individually rare, orphan diseases are actually collectively common, with an estimated 350 million sufferers worldwide. Since the introduction of the US Orphan Drug Act more than 30 years ago, the number of orphan designations has skyrocketed and experts are predicting worldwide sales of these drugs will reach $176 billion by the end of 20201. With the cost of developing orphan drugs comparatively less than non-orphan products, appreciable regulatory support for innovative program design, and with the possibility of demonstrating significant intellectual property value, interest and investment in orphan disease development programs has been explosive.

Read More

About Worldwide Clinical Trials
Worldwide Clinical Trials provides full-service drug development services to the pharmaceutical and biotechnology industries from Early Phase and Bioanalytical Sciences through Phase II and III trials to Peri-Approval studies. We believe successful drug development strategically balances science, medicine, operations and commercial intelligence. We approach every Phase I-IV drug development program as unique. Our mission is to foster the development of life changing medicines by integrating innovative methodology, rigorous science and efficient technology.

Schedule a Meeting: